Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONMED CorpCNMD · Entity 4691 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONMED Corp
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,527 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 668 · Balance 15,527 |
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-06-01 | Direct | 5,772 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 5,772 · Balance 5,772 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. |
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-06-02 | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-02 · Exercise / conversion · Disposed 668 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2017 Filed Jun 2, 2017 19:32 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 2,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-020267 · form4.xml · nonDerivative · entry 1 Farkas Charles · CIK 0001615538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 19:05 UTC | CONMED Corp CNMD · Entity 4691 | PurchaseCommon Stock | 180 | $44.41 | $7,993.80 |
DisclosureSEC source: 0001127602-17-013826 · form4.xml · nonDerivative · entry 1 Farkas Charles · CIK 0001615538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,505 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 27, 2017. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 16:16 UTC | CONMED Corp CNMD · Entity 4691 | PurchaseCommon Stock | 305 | $44.65 | $13,618.25 |
DisclosureSEC source: 0001127602-17-000401 · form4.xml · nonDerivative · entry 1 Farkas Charles · CIK 0001615538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2016. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 15:15 UTC | CONMED Corp CNMD · Entity 4691 | PurchaseCommon Stock | 336 | $40.04 | $13,453.44 |
DisclosureSEC source: 0001127602-16-063857 · form4.xml · nonDerivative · entry 1 Farkas Charles · CIK 0001615538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.